Axsome Therapeutics, Inc (AXSM)

Price$255.17

Value ScoreD

Growth ScoreB

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)63.62%

Price vs S&P 500 (4W)10.65%

VGM Score63.64

Market Capitalization$13.13B

All Metrics

Book Value / Share (Quarterly)$1.06

P/TBV (Annual)410.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)133.68%

Cash Flow / Share (Quarterly)$-1.38

Price vs S&P 500 (YTD)30.76%

Gross Margin (TTM)92.60%

Net Profit Margin (TTM)-26.59%

EPS (TTM)$-3.74

10-Day Avg Trading Volume0.75M

EPS Excl Extra (TTM)$-3.74

EPS (Annual)$-3.68

ROI (Annual)-118.68%

Gross Margin (Annual)92.56%

Net Profit Margin (5Y Avg)-1038.72%

Cash / Share (Quarterly)$5.93

Revenue Growth QoQ (YoY)57.42%

ROA (Last FY)-50.57%

Revenue Growth TTM (YoY)63.88%

EBITD / Share (TTM)$-3.52

ROE (5Y Avg)-345.24%

Operating Margin (TTM)-25.91%

Cash Flow / Share (Annual)$-2.63

P/B Ratio240.55x

P/B Ratio (Quarterly)158.39x

Net Income / Employee (Annual)$-198,000

EV / Revenue (TTM)18.39x

Net Interest Coverage (TTM)-27.02x

ROA (TTM)-27.77%

EPS Incl Extra (Annual)$-3.68

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)1.27x

3-Month Avg Trading Volume0.69M

52-Week Price Return134.80%

Revenue / Employee (TTM)$765,700

Tangible BV / Share (Quarterly)$0.30

P/S Ratio (Annual)20.57x

Asset Turnover (Annual)0.68x

52-Week High$257.44

Operating Margin (5Y Avg)-1009.22%

EPS Excl Extra (Annual)$-3.68

CapEx CAGR (5Y)57.20%

Tangible BV CAGR (5Y)18.82%

26-Week Price Return71.42%

Quick Ratio (Annual)1.99x

13-Week Price Return59.10%

Total Debt / Equity (Annual)3.25x

Current Ratio (Quarterly)1.39x

Enterprise Value$13.02B

Asset Turnover (TTM)1.04x

Book Value / Share Growth (5Y)-24.82%

Revenue / Employee (Annual)$690,300

Pretax Margin (Annual)-28.77%

Cash / Share (Annual)$6.43

3-Month Return Std Dev44.60%

Net Income / Employee (TTM)$-203,600

ROE (Last FY)-503.89%

Net Interest Coverage (Annual)-34.56x

EPS Basic Excl Extra (Annual)$-3.68

Receivables Turnover (TTM)3.43x

Total Debt / Equity (Quarterly)3.61x

EPS Incl Extra (TTM)$-3.74

ROI (TTM)-70.44%

P/S Ratio (TTM)18.54x

Pretax Margin (5Y Avg)-1038.72%

Revenue / Share (Annual)$12.83

Tangible BV / Share (Annual)$0.20

Forward P/E136.09x

Price vs S&P 500 (52W)112.12%

Year-to-Date Return38.95%

5-Day Price Return9.23%

EPS Normalized (Annual)$-3.68

ROA (5Y Avg)-70.30%

Net Profit Margin (Annual)-28.69%

Month-to-Date Return8.23%

Cash Flow / Share (TTM)$-4.39

EBITD / Share (Annual)$-3.43

Operating Margin (Annual)-27.74%

LT Debt / Equity (Annual)0.93x

ROI (5Y Avg)-108.06%

LT Debt / Equity (Quarterly)2.16x

EPS Basic Excl Extra (TTM)$-3.74

P/TBV (Quarterly)552.81x

P/B Ratio (Annual)71.94x

Inventory Turnover (TTM)2.19x

Pretax Margin (TTM)-26.66%

Book Value / Share (Annual)$1.16

Price vs S&P 500 (13W)50.02%

Beta0.62x

Revenue / Share (TTM)$13.83

ROE (TTM)-260.01%

52-Week Low$96.09

vGradeD

gGradeB

mGradeA

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-1.26est. -0.91

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.27

4.30

Industry Peers — Pharmaceuticals(554)

Symbol	Value Score	Growth Score	Momentum Score	Price
AXSMAxsome Therapeutics, Inc	D	B	A	$255.17
LLYEli Lilly & Co.	D	B	B	$1133.00
JNJJohnson & Johnson	D	C	B	$240.87
ABBVABBVIE INC.	D	C	C	$227.73
MRKMerck & Co., Inc.	C	C	B	$119.05
NVSNovartis AG	C	C	B	$153.07
AZNAstraZeneca PLC	C	B	C	$178.75
NVONovo-Nordisk A/S	B	B	B	$43.88
ABTAbbott Laboratories	C	C	D	$88.18
PFEPfizer Inc.	B	C	C	$26.21
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	B	$34.63

About

Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders with limited existing treatment options. The company's pipeline includes four late-stage candidates: AXS-05, AXS-07, AXS-12, and AXS-14, addressing multiple indications in neurology and psychiatry. Axsome targets underserved patient populations where unmet medical needs remain high.